Press Releases

Lexicon Pharmaceuticals Provides an Update on the Sotagliflozin Type 2 Diabetes Program	Mar 19, 2020
Lexicon Pharmaceuticals Announces Additional Data on Telotristat Ethyl’s Antiproliferative Effects in Patients with Carcinoid Syndrome	Mar 13, 2020
Lexicon Pharmaceuticals Reports Fourth Quarter and Full-Year 2019 Financial Results and Provides a Business Update	Mar 12, 2020
Lexicon Pharmaceuticals to Host Fourth Quarter and Full-year 2019 Financial Results Conference Call and Webcast on March 12, 2020	Mar 05, 2020
Lexicon Pharmaceuticals Announces Real-World Data on Telotristat Ethyl’s Antiproliferative Effects in Patients with Carcinoid Syndrome	Jan 24, 2020
Lexicon Pharmaceuticals Announces Poster Presentation at the ASCO 2020 Gastrointestinal Cancers Symposium	Jan 20, 2020
Lexicon Pharmaceuticals to Present at Upcoming Investor Conference	Jan 06, 2020
Lexicon Pharmaceuticals Announces Topline Phase 3 Data for Sotagliflozin in Type 2 Diabetes	Dec 20, 2019
Lexicon Pharmaceuticals Announces Positive Topline Phase 1 Data for LX9211	Dec 05, 2019
Lexicon Pharmaceuticals Completes Safety Review of Initial Safety Run-in Cohort of Tele-ABC Study, a Phase 2 Clinical Study of Telotristat Ethyl in Biliary Tract Cancer	Dec 03, 2019